AU2001275959A1 - Method of treating the syndrome of type 2 diabetes in humans - Google Patents
Method of treating the syndrome of type 2 diabetes in humansInfo
- Publication number
- AU2001275959A1 AU2001275959A1 AU2001275959A AU7595901A AU2001275959A1 AU 2001275959 A1 AU2001275959 A1 AU 2001275959A1 AU 2001275959 A AU2001275959 A AU 2001275959A AU 7595901 A AU7595901 A AU 7595901A AU 2001275959 A1 AU2001275959 A1 AU 2001275959A1
- Authority
- AU
- Australia
- Prior art keywords
- diabetes
- syndrome
- humans
- treating
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63893000A | 2000-08-15 | 2000-08-15 | |
US09/638,930 | 2000-08-15 | ||
PCT/US2001/022466 WO2002013759A2 (en) | 2000-08-15 | 2001-07-17 | Method of treating the syndrome of type 2 diabetes in humans |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001275959A1 true AU2001275959A1 (en) | 2002-02-25 |
Family
ID=24562030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001275959A Abandoned AU2001275959A1 (en) | 2000-08-15 | 2001-07-17 | Method of treating the syndrome of type 2 diabetes in humans |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1365756A2 (en) |
AU (1) | AU2001275959A1 (en) |
WO (1) | WO2002013759A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100469500B1 (en) | 2002-06-29 | 2005-02-02 | 엘지전자 주식회사 | Tranceiver appratus for mobile communication terminal |
JP5128578B2 (en) | 2006-04-04 | 2013-01-23 | エモディス ゲーエムベーハー | Use of κ-opioid receptor antagonist-containing compositions for the treatment of dissociative disorders |
SI2724722T1 (en) * | 2006-10-20 | 2017-07-31 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
ES2629185T3 (en) | 2011-08-26 | 2017-08-07 | Deutsche Diabetes-Forschungsgesellschaft e. V. | Morphinan derivatives for the treatment of diabetes and related disorders |
EP2561866A1 (en) * | 2011-08-26 | 2013-02-27 | Heinrich-Heine-Universität Düsseldorf | Morphinan-derivatives for treating diabetes and related disorders |
CN107405343A (en) | 2014-11-07 | 2017-11-28 | 明尼苏达大学董事会 | Salt and composition available for treatment disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3809999A (en) * | 1998-05-18 | 1999-12-06 | Novo Nordisk A/S | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
-
2001
- 2001-07-17 EP EP01953517A patent/EP1365756A2/en not_active Withdrawn
- 2001-07-17 WO PCT/US2001/022466 patent/WO2002013759A2/en not_active Application Discontinuation
- 2001-07-17 AU AU2001275959A patent/AU2001275959A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002013759A2 (en) | 2002-02-21 |
WO2002013759A3 (en) | 2003-07-10 |
EP1365756A2 (en) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001276952A1 (en) | Method of treating the syndrome of coronary heart disease risk factors in humans | |
AU2001256755A1 (en) | Biosensor and method for manufacturing the same | |
AU2001249881A1 (en) | Method of treating the heart | |
AU2002215230A1 (en) | Internet commerce system and the method | |
AU2001262723A1 (en) | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | |
AU2002219945A1 (en) | Composition and method for treating snoring | |
AU5294100A (en) | Method and compositions for treating the inflammatory response | |
AU2002232479A1 (en) | Low-fat nut spread composition and process for making the same | |
AU4288100A (en) | Drying device and method for producing the same | |
AU2002219002A1 (en) | Method and device for treating the surfaces of items | |
AU2001276295A1 (en) | Electric component, method for the production thereof, and its use | |
AU2002231095A1 (en) | Method and composition for the treatment of diabetic neuropathy | |
AU1359801A (en) | Methods and compositions for treating reward deficiency syndrome | |
EP1217051A3 (en) | Surface treating agent for ligneous floorings and process for manufacturing the same | |
AU1468601A (en) | Sorbent, method of making the sorbent, and method of using the sorbent in fixed bed applications | |
AU2001233932A1 (en) | Method and composition | |
AU2001275959A1 (en) | Method of treating the syndrome of type 2 diabetes in humans | |
MXPA03004017A (en) | Method for the treatment of inflammation. | |
HUP0401577A3 (en) | Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses | |
AU4198899A (en) | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process | |
AU2002239775A1 (en) | Chemical-library composition and method | |
AU2002315032A1 (en) | Improved method of treating the syndrome of type 2 diabetes in humans | |
AU2001282663A1 (en) | Composition comprising chromium picolinate, method of preparing the same and usethereof | |
AU2001257467A1 (en) | Footwear structure and method of forming the same | |
AU2002256967A1 (en) | Treating or reducing the risk of cardiovascular disease |